A pilot study on the efficacy of epiroprim against developmental stages of Toxoplasma gondii and Pneumocystis carinii in animal models.
The new bacteriocidal drug epiroprim (Ro-11-8958) was tested (alone or in combination with dapsone) on its efficacy against Toxoplasma gondii and Pneumocystis carinii in their hosts: laboratory mice and/or nude mice/rats, and was compared to the curative effects of the recent drugs of choice. The experiments clearly pointed out that epiroprim has significant effects on the reduction of both parasites when given alone. In combination with dapsone epiroprim led to a complete cure of toxoplasmosis in mice. This finding is of some importance for AIDS patients mostly suffering from bacteriosis and parasitosis at the same time.
Mehlhorn
H
H
Department of Parasitology, Ruhr University, Bochum, Germany.
Dankert
W
W
Hartman
P G
PG
Then
R L
RL
D000818:Animals; D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents / Q000627:therapeutic use; D003622:Dapsone / Q000627:therapeutic use; D004359:Drug Therapy, Combination / Q000627:therapeutic use; D005260:Female; D005493:Folic Acid Antagonists / Q000627:therapeutic use; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D008819:Mice, Nude; D016513:Mice, SCID; D010865:Pilot Projects; D011010:Pneumocystis / Q000187:drug effects*; D016720:Pneumocystis Infections / Q000188:drug therapy*; D011739:Pyrimethamine / Q000627:therapeutic use; D051381:Rats; D011923:Rats, Nude; D012965:Sodium Chloride / Q000627:therapeutic use; D013411:Sulfadiazine / Q000627:therapeutic use; D014122:Toxoplasma / Q000187:drug effects*; D014124:Toxoplasmosis, Animal / Q000188:drug therapy*; D014295:Trimethoprim / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D005493:Folic Acid Antagonists; D013411:Sulfadiazine; D012965:Sodium Chloride; D003622:Dapsone; C082896:epiroprim; D014295:Trimethoprim; D011739:Pyrimethamine